Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Double-Blind, Multicenter, Randomized, Placebo-Controlled Trial With Aztreonam Lysinate for Inhalation in Cystic Fibrosis Patients With Pulmonary P. Aeruginosa Requiring Frequent Antibiotics (AIR-CF2)
Brief Summary: The purpose of this study was to evaluate the safety and efficacy of aztreonam for inhalation solution (AZLI) in patients with cystic fibrosis (CF) and lung infection due to Pseudomonas aeruginosa (PA).


Options:
A: Arm Label: Cohort 1 - 280 mg ARIKACE™; Type: EXPERIMENTAL; Interventions: Drug: ARIKACE™ | Arm Label: Cohort 1 - Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Cohort 2 - 560 mg ARIKACE™; Type: EXPERIMENTAL; Interventions: Drug: ARIKACE™ | Arm Label: Cohort 2 - Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: ARIKACE™; Assigned to Arm(s): Cohort 1 - 280 mg ARIKACE™, Cohort 2 - 560 mg ARIKACE™ | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Cohort 1 - Placebo, Cohort 2 - Placebo
B: Arm Label: Placebo (pooled two times a day [BID]/three times a day [TID]); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo two times a day (BID)/three times a day (TID) | Arm Label: AZLI (pooled two times a day [BID]/three times a day [TID]); Type: EXPERIMENTAL; Interventions: Drug: AZLI 75 mg two times a day (BID)/three times a day (TID) | Intervention Type: DRUG; Name: AZLI 75 mg two times a day (BID)/three times a day (TID); Assigned to Arm(s): AZLI (pooled two times a day [BID]/three times a day [TID]) | Intervention Type: DRUG; Name: Placebo two times a day (BID)/three times a day (TID); Assigned to Arm(s): Placebo (pooled two times a day [BID]/three times a day [TID])
C: Arm Label: 32.50 mg Ciprofloxacin DPI (BAYQ3939); Type: EXPERIMENTAL; Interventions: Drug: Ciprofloxacin (Cipro Inhale, BAYQ3939) | Arm Label: 48.75 mg Ciprofloxacin DPI (BAYQ3939); Type: EXPERIMENTAL; Interventions: Drug: Ciprofloxacin (Cipro Inhale, BAYQ3939) | Arm Label: Matching Placebo for 32.50 mg; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Matching Placebo for 48.75 mg; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Ciprofloxacin (Cipro Inhale, BAYQ3939); Assigned to Arm(s): 32.50 mg Ciprofloxacin DPI (BAYQ3939) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Matching Placebo for 32.50 mg | Intervention Type: DRUG; Name: Ciprofloxacin (Cipro Inhale, BAYQ3939); Assigned to Arm(s): 48.75 mg Ciprofloxacin DPI (BAYQ3939) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Matching Placebo for 48.75 mg
D: Arm Label: Arikayce™; Type: EXPERIMENTAL; Interventions: Drug: Liposomal amikacin for inhalation (Arikayce™) using the PARI Investigational eFlow® Nebulizer. | Arm Label: TOBI®; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tobramycin inhalation solution using a PARI LC® Plus nebulizer. | Intervention Type: DRUG; Name: Liposomal amikacin for inhalation (Arikayce™) using the PARI Investigational eFlow® Nebulizer.; Assigned to Arm(s): Arikayce™ | Intervention Type: DRUG; Name: Tobramycin inhalation solution using a PARI LC® Plus nebulizer.; Assigned to Arm(s): TOBI®

Answer: B